Michael G. Raab's Insider Trades & SAST Disclosures
Michael G. Raab's most recent trade in Ardelyx Inc was a trade of 41,666 Common Stock done at an average price of $4.3 . Disclosure was reported to the exchange on May 2, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Michael G. Raab.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 4.25 per share. | 02 May 2025 | 41,666 | 1,594,754 (2%) | 0% | 4.3 | 177,168 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 02 May 2025 | 20,833 | 1,636,420 (2%) | 0% | 1.0 | 20,625 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2025 | 20,833 | 415,834 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 4.59 per share. | 04 Apr 2025 | 41,666 | 1,615,587 (2%) | 0% | 4.6 | 191,151 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 04 Apr 2025 | 20,833 | 1,657,253 (2%) | 0% | 1.0 | 20,625 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2025 | 20,833 | 436,667 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.36 per share. | 07 Mar 2025 | 41,668 | 1,635,138 (2%) | 0% | 5.4 | 223,199 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 07 Mar 2025 | 20,834 | 1,676,806 (2%) | 0% | 1.0 | 20,626 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2025 | 20,834 | 457,500 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 855,326 | 855,326 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 570,217 | 1,655,972 (2%) | 0% | 0 | Common Stock | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.62 per share. | 20 Feb 2025 | 22,964 | 1,085,755 (1%) | 0% | 5.6 | 129,124 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.36 per share. | 31 Jan 2025 | 41,666 | 1,108,719 (1%) | 0% | 5.4 | 223,355 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 20,833 | 478,334 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 31 Jan 2025 | 20,833 | 1,150,385 (1%) | 0% | 1.0 | 20,625 | Common Stock |
| Ardelyx Inc | Raab Michael G. | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.26 per share. | 10 Dec 2024 | 25,000 | 1,150,385 (1%) | 0% | 5.3 | 131,620 | Common Stock |
| Ardelyx Inc | Raab Michael G. | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 25,000 | 520,000 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 10 Dec 2024 | 25,000 | 1,175,385 (1%) | 0% | 1.0 | 24,750 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.38 per share. | 25 Nov 2024 | 25,000 | 1,150,385 (1%) | 0% | 5.4 | 134,483 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 4.79 per share. | 20 Nov 2024 | 31,980 | 1,175,385 (1%) | 0% | 4.8 | 153,328 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 4.90 per share. | 11 Nov 2024 | 2,743 | 1,207,365 (1%) | 0% | 4.9 | 13,441 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 28 Oct 2024 | 25,000 | 1,235,108 (1%) | 0% | 1.0 | 24,750 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2024 | 25,000 | 545,000 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.91 per share. | 28 Oct 2024 | 25,000 | 1,210,108 (1%) | 0% | 5.9 | 147,740 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 6.01 per share. | 11 Oct 2024 | 7,500 | 1,210,108 (1%) | 0% | 6.0 | 45,075 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 6.07 per share. | 26 Sep 2024 | 3,000 | 1,217,608 (1%) | 0% | 6.1 | 18,210 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 11 Sep 2024 | 35,000 | 1,255,608 (1%) | 0% | 1.0 | 34,650 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2024 | 35,000 | 570,000 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.61 per share. | 11 Sep 2024 | 35,000 | 1,220,608 (1%) | 0% | 5.6 | 196,399 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 6.22 per share. | 27 Aug 2024 | 7,500 | 1,219,509 (1%) | 0% | 6.2 | 46,635 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.86 per share. | 20 Aug 2024 | 32,225 | 1,227,009 (1%) | 0% | 5.9 | 188,848 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.71 per share. | 12 Aug 2024 | 1,229 | 1,259,234 (1%) | 0% | 5.7 | 7,018 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 29 Jul 2024 | 30,000 | 1,290,463 (1%) | 0% | 1.0 | 29,700 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jul 2024 | 30,000 | 605,000 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.64 per share. | 29 Jul 2024 | 30,000 | 1,260,463 (1%) | 0% | 5.6 | 169,314 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.97 per share. | 15 Jul 2024 | 7,500 | 1,260,463 (1%) | 0% | 6.0 | 44,768 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 6.59 per share. | 28 Jun 2024 | 2,310 | 1,267,963 (1%) | 0% | 6.6 | 15,223 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 6.65 per share. | 13 Jun 2024 | 35,000 | 1,270,273 (1%) | 0% | 6.6 | 232,743 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 35,000 | 665,000 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 13 Jun 2024 | 35,000 | 1,305,273 (1%) | 0% | 1.0 | 34,650 | Common Stock |
| Tempest Therapeutics Inc | Michael G. Raab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 16,000 | 16,000 | - | - | Stock Option (right to buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 42,467 | 42,467 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 11,847 | 95,443 (0%) | 0% | 0 | Common Stock | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 6.72 per share. | 29 May 2024 | 7,500 | 1,270,273 (1%) | 0% | 6.7 | 50,390 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 7.81 per share. | 21 May 2024 | 31,484 | 1,277,773 (1%) | 0% | 7.8 | 245,922 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 7.99 per share. | 14 May 2024 | 3,000 | 1,307,933 (1%) | 0% | 8.0 | 23,970 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 29 Apr 2024 | 30,000 | 1,340,933 (2%) | 0% | 1.0 | 29,700 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2024 | 30,000 | 670,000 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 6.40 per share. | 29 Apr 2024 | 30,000 | 1,310,933 (1%) | 0% | 6.4 | 192,057 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 7.06 per share. | 15 Apr 2024 | 7,500 | 1,310,933 (1%) | 0% | 7.1 | 52,924 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 7.31 per share. | 01 Apr 2024 | 1,518 | 1,318,433 (2%) | 0% | 7.3 | 11,097 | Common Stock |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 15,000 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.80 per share. | 05 Mar 2024 | 15,000 | 83,596 (0%) | 0% | 2.8 | 42,000 | Common Stock |
| Ardelyx Inc | Michael Raab G. | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 8.75 per share. | 20 Feb 2024 | 22,917 | 1,319,951 (2%) | 0% | 8.7 | 200,439 | Common Stock |
| Ardelyx Inc | Michael Raab G. | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2024 | 605,904 | 605,904 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2024 | 475,000 | 1,342,868 (2%) | 0% | 0 | Common Stock | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 3.55 per share. | 21 Aug 2023 | 11,419 | 876,236 (1%) | 0% | 3.6 | 40,558 | Common Stock |
| Tempest Therapeutics Inc | Michael G. Raab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 8,200 | 8,200 | - | - | Stock Option (right to buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 30,474 | 30,474 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 8,584 | 68,596 (0%) | 0% | 0 | Common Stock | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 3.65 per share. | 23 May 2023 | 11,357 | 887,655 (1%) | 0% | 3.7 | 41,489 | Common Stock |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.32 per share. | 17 Mar 2023 | 15,000 | 64,420 (0%) | 0% | 3.3 | 49,800 | Common Stock |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2023 | 15,000 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Sale of securities on an exchange or to another person at price $ 11.33 per share. | 17 Mar 2023 | 4,408 | 60,012 (0%) | 0% | 11.3 | 49,943 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 3.00 per share. | 21 Feb 2023 | 13,449 | 896,012 (1%) | 0% | 3.0 | 40,360 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 1,124,000 | 1,124,000 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 250,000 | 909,461 (1%) | 0% | 0 | Common Stock | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 1.95 per share. | 22 Nov 2022 | 5,936 | 659,461 (1%) | 0% | 1.9 | 11,571 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 1.94 per share. | 22 Nov 2022 | 162 | 665,518 (1%) | 0% | 1.9 | 314 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 1.94 per share. | 22 Nov 2022 | 121 | 665,397 (1%) | 0% | 1.9 | 235 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 0.62 per share. | 31 Aug 2022 | 3,000 | 665,680 (1%) | 0% | 0.6 | 1,856 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 0.98 per share. | 22 Aug 2022 | 6,016 | 662,810 (1%) | 0% | 1.0 | 5,918 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 0.97 per share. | 22 Aug 2022 | 76 | 662,680 (1%) | 0% | 1.0 | 74 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 0.98 per share. | 22 Aug 2022 | 54 | 662,756 (1%) | 0% | 1.0 | 53 | Common Stock |
| Tempest Therapeutics Inc | Michael G. Raab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 3,500 | 3,500 | - | - | Stock Option (Right to Buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 45,423 | 45,423 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 12,671 | 49,420 (0%) | 0% | 0 | Common Stock | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 0.65 per share. | 06 Jun 2022 | 101,480 | 670,970 (1%) | 0% | 0.7 | 66,053 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 0.64 per share. | 06 Jun 2022 | 2,144 | 668,826 (1%) | 0% | 0.6 | 1,363 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 0.67 per share. | 20 May 2022 | 6,124 | 772,450 (1%) | 0% | 0.7 | 4,112 | Common Stock |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.79 per share. | 02 May 2022 | 15,000 | 51,749 (0%) | 0% | 4.8 | 71,850 | Common Stock |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2022 | 15,000 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Sale of securities on an exchange or to another person at price $ 6.99 per share. | 02 May 2022 | 15,000 | 36,749 (0%) | 0% | 7.0 | 104,891 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 0.67 per share. | 22 Feb 2022 | 6,229 | 775,574 (1%) | 0% | 0.7 | 4,173 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 700,000 | 700,000 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 150,000 | 781,803 (1%) | 0% | 0 | Common Stock | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 0.99 per share. | 22 Nov 2021 | 2,607 | 631,803 (0%) | 0% | 1.0 | 2,586 | Common Stock |
| Tempest Therapeutics Inc | Michael G. Raab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Sep 2021 | 6,635 | 6,635 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 1.32 per share. | 20 Aug 2021 | 2,573 | 329,730 (0%) | 0% | 1.3 | 3,396 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 03 Aug 2021 | 267,892 | 482,646 (0%) | 0% | 0.5 | 144,662 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2021 | 267,892 | 0 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.64 per share. | 03 Aug 2021 | 150,343 | 332,303 (0%) | 0% | 1.6 | 246,563 | Common Stock |
| Tempest Therapeutics Inc | Michael G. Raab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2021 | 16,784 | 16,784 | - | - | Stock Option (Right to Buy) | |
| Tempest Therapeutics Inc | Michael G. Raab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2021 | 9,660 | 9,660 | - | - | Stock Option (Right to Buy) | |
| Tempest Therapeutics Inc | Michael G. Raab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2021 | 4,830 | 4,830 | - | - | Stock Option (Right to Buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 36,111 | 36,111 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 10,115 | 36,749 (0%) | 0% | 0 | Common Stock | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 7.09 per share. | 20 May 2021 | 2,534 | 214,754 (0%) | 0% | 7.1 | 17,960 | Common Stock |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 5,634 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.56 per share. | 18 May 2021 | 5,634 | 26,634 (0%) | 0% | 7.6 | 42,593 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 6.88 per share. | 22 Feb 2021 | 2,534 | 217,288 (0%) | 0% | 6.9 | 17,440 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges